

# Anti-PD-1 (Pembrolizumab) Biotinylated Antibody


rev 06/20

CATALOG NO.: A2073-50 (50 µg)

**BACKGROUND DESCRIPTION:** Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.

<b>ANTIBODY TYPE:</b>	Monoclonal
<b>CONCENTRATION:</b>	0.5 mg/ml
<b>HOST/ISOTYPE:</b>	Recombinant / Human IgG4
<b>IMMUNOGEN:</b>	Human programmed cell death 1 receptor (PD-1)
<b>PURIFICATION:</b>	Affinity purified
<b>FORM:</b>	Liquid
<b>FORMULATION:</b>	In PBS, 30% glycerol, 0.5% BSA, 0.5 mM EDTA and 0.03% proclin, pH 7.2
<b>SPECIES REACTIVITY:</b>	Human
<b>STORAGE CONDITIONS:</b>	Store at -20°C. Avoid freeze / thaw cycles
<b>APPLICATIONS AND USAGE:</b>	ELISA 0.5 - 1 µg/ml

This information is only intended as a guide. The optimal dilutions must be determined by the user



Direct ELISA shows that Anti-PD-1 (Pembrolizumab) Biotinylated antibody can bind to immobilized recombinant human PD-1 within a concentration range of 0-10 ng/ml

## RELATED PRODUCTS:

Anti-PD-L1 (Atezolizumab), Humanized Antibody (A1305)  
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)  
 Anti-PD-1 (CD279), Rabbit Monoclonal Antibody (A1825)  
 Anti-PD-1 (Nivolumab), Humanized Antibody (A1307)  
 Anti-PD-1 Biotinylated Antibody (A1996)

**FOR RESEARCH USE ONLY! Not to be used on humans**